Weizmann Institute Drug, TOOKAD(r) Soluble, Approved in Mexico for Prostate Cancer Therapy
Monday, January 4, 2016 - 14:41
in Health & Medicine
The Weizmann Institute-developed TOOKAD(r) Soluble has been approved in Mexico for use in treating prostate cancer. The therapy, which has no side effects, offers men with early-stage prostate cancer a much-needed treatment alternative. Phase III trials have taken place in Europe and continue in the U.S.